摘要
泛素-蛋白酶体途径参与各种生物学过程。几种致癌的E3连接酶以针对泛素介导的降解肿瘤抑制蛋白为靶点。另外,一些其他的E3连接酶还作为一种专门针对癌基因产物的肿瘤抑制。这些E3连接酶诱导致癌信号减弱控制作用和肿瘤抑制通路,导致细胞转化之间的不平衡,和多种人类恶性肿瘤包括口腔和头颈部肿瘤的生长和转移。细胞周期蛋白依赖性激酶(CDK)抑制剂p27Kip1的促进降解已在口腔,头颈部癌症中发现,并与不良预后相关。SCFSkp2,KPC复合体,Pirh2和crl4ddb2 Artemis被报道称为E3连接酶靶向p27kip1蛋白降解。据报道,在口腔癌中,Skp2和Pirh2蛋白的超表达与预后不良效果相关。因此,化学抑制剂对E3连接酶的口腔癌的治疗是可行的。一些潜在的抑制SCFSkp2 E3连接酶活性的化合物已被报道。此外,HECT E3连接酶 WWP型家族 和Smurf1也参与人类口腔癌的发展。因此,小分子抑制剂和HECT类E3连接酶可被讨论为抗口腔癌的药物。
关键词: 化学抑制剂,E3连接酶,p27kip1,口腔癌,单克隆抗体Smurf1,Skp2,泛素-蛋白酶体系统,WWP。
Current Cancer Drug Targets
Title:E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers
Volume: 16 Issue: 2
Author(s): Kazuma Masumoto and Masatoshi Kitagawa
Affiliation:
关键词: 化学抑制剂,E3连接酶,p27kip1,口腔癌,单克隆抗体Smurf1,Skp2,泛素-蛋白酶体系统,WWP。
摘要: The ubiquitin-proteasome pathway is involved in various biological processes. Several oncogenic E3 ligases target tumor suppressor proteins for ubiquitin-mediated degradation. Alternatively, some other E3 ligases play as a tumor suppressor specifically targeting oncogene products. Deregulation of these E3 ligases induces unbalance between oncogenic signal and tumor suppressor pathway and leads to cellular transformation, tumor growth and metastasis in various human malignancies including oral, and head and neck cancers. Facilitated degradation of the cyclin-dependent kinase (CDK) inhibitor p27Kip1 has been observed in oral, and head and neck cancers, and is correlated with their poor prognosis. SCFSkp2, KPC complex, Pirh2 and CRL4DDB2-Artemis have been reported as E3 ligases targeting p27Kip1 for degradation. In oral cancers, it is reported that overexpression of Skp2 and Pirh2 is associated with poor prognosis. Thus, chemical inhibitors against these E3 ligases are applicable for oral cancer therapy. Some potential compounds that inhibit E3 ligase activity of SCFSkp2 have been reported. Moreover, the HECT-type E3 ligase WWP family and Smurf1 are also involved in the development and growth of human oral cancers. Therefore, small molecule inhibitors against HECT-type E3 ligases are discussed as anti-oral cancer drugs.
Export Options
About this article
Cite this article as:
Kazuma Masumoto and Masatoshi Kitagawa , E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122336
DOI https://dx.doi.org/10.2174/1568009616666151112122336 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Chitosan Surface-Modified PLGA Nanoparticles: Preparation, Characterization, and Evaluation of their In Vitro Drug-Release Behaviors and Cytotoxicities
Current Nanoscience Dinuclear Berenil-Platinum (II) Complexes as Modulators of Apoptosis in Human MCF-7 and MDA-MB231 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Pattern of Care for Skin Cancers - Canada and France
Current Cancer Therapy Reviews Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Specific Hemosiderin Deposition in Spleen Induced by a Low Dose of Cisplatin: Altered Iron Metabolism and Its Implication as an Acute Hemosiderin Formation Model
Current Drug Metabolism Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents The Yin and Yang of CD4+ Regulatory T Cells in Autoimmunity and Cancer
Current Medicinal Chemistry Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Objective Biomarkers or Symptom Scores for the Classification of Fibromyalgia Syndrome?
Current Rheumatology Reviews Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets Repurposing of Alexidine Dihydrochloride as an Apoptosis Initiator and Cell Cycle Inhibitor in Human Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes That Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting
Current Drug Targets